Sesen Bio, Inc. (SESN)
|52 Week Range||0.365-0.965|
|1y Target Est||-|
|DCF Unlevered||SESN DCF ->|
|DCF Levered||SESN LDCF ->|
|Debt / Equity||19.59%||Neutral|
Upgrades & Downgrades
Latest SESN news
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?
30 November 2022
SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio
22 November 2022
Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN).
7 Cheap Penny Stocks To Buy For Under $1 Right Now
7 November 2022
Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know
21 October 2022
In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.
Best Momentum Stocks to Buy for August 15th
15 August 2022
BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
19 July 2022
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Why Shares Of Sesen Bio Are Down 28% Today
18 July 2022
Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of i...
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
18 July 2022
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIB...
Which Industries Are Penny Stocks Investors Watching Right Now
10 July 2022
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and I...
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >